PetMed Express, Inc. (NASDAQ:PETS) – Northcoast Research increased their FY2018 earnings per share estimates for PetMed Express in a report released on Monday, Zacks Investment Research reports. Northcoast Research analyst E. Snyder now forecasts that the company will post earnings of $1.57 per share for the year, up from their prior forecast of $1.40. Northcoast Research currently has a “Buy” rating and a $54.00 target price on the stock. Northcoast Research also issued estimates for PetMed Express’ Q2 2019 earnings at $0.41 EPS and FY2019 earnings at $1.61 EPS.
A number of other equities research analysts also recently issued reports on the stock. Sidoti raised shares of PetMed Express from a “neutral” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Thursday, August 24th. BidaskClub downgraded shares of PetMed Express from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, August 22nd. Zacks Investment Research raised shares of PetMed Express from a “sell” rating to a “hold” rating and set a $50.00 target price for the company in a report on Friday, October 20th. Noble Financial reaffirmed a “hold” rating on shares of PetMed Express in a report on Wednesday, July 26th. Finally, Craig Hallum reissued a “hold” rating and set a $40.00 price objective (down previously from $43.00) on shares of PetMed Express in a report on Monday, August 21st. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and three have issued a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $42.00.
ILLEGAL ACTIVITY NOTICE: This piece was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was stolen and republished in violation of US & international copyright and trademark law. The original version of this piece can be read at https://www.dispatchtribunal.com/2017/11/12/petmed-express-inc-pets-to-post-fy2018-earnings-of-1-57-per-share-northcoast-research-forecasts.html.
Shares of PetMed Express (NASDAQ PETS) opened at $37.29 on Wednesday. PetMed Express has a 12 month low of $19.21 and a 12 month high of $50.90. The firm has a market cap of $768.32, a price-to-earnings ratio of 25.03, a price-to-earnings-growth ratio of 2.25 and a beta of 1.09.
PetMed Express (NASDAQ:PETS) last announced its earnings results on Monday, October 23rd. The company reported $0.43 earnings per share for the quarter, beating analysts’ consensus estimates of $0.30 by $0.13. The business had revenue of $66.70 million during the quarter, compared to analyst estimates of $63.41 million. PetMed Express had a net margin of 11.58% and a return on equity of 31.46%. The company’s quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the business earned $0.24 EPS.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, November 17th. Investors of record on Monday, November 6th will be given a $0.20 dividend. This represents a $0.80 dividend on an annualized basis and a yield of 2.15%. The ex-dividend date is Friday, November 3rd. PetMed Express’s dividend payout ratio (DPR) is currently 53.69%.
In other news, Director Ronald J. Korn sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, October 27th. The shares were sold at an average price of $35.57, for a total transaction of $35,570.00. Following the transaction, the director now directly owns 73,833 shares of the company’s stock, valued at $2,626,239.81. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 4.00% of the company’s stock.
A number of institutional investors and hedge funds have recently made changes to their positions in PETS. Acrospire Investment Management LLC acquired a new stake in PetMed Express in the second quarter valued at approximately $110,000. Pinebridge Investments L.P. boosted its stake in PetMed Express by 1.0% in the second quarter. Pinebridge Investments L.P. now owns 2,704 shares of the company’s stock valued at $110,000 after acquiring an additional 27 shares in the last quarter. Sei Investments Co. boosted its stake in PetMed Express by 50,142.9% in the third quarter. Sei Investments Co. now owns 3,517 shares of the company’s stock valued at $117,000 after acquiring an additional 3,510 shares in the last quarter. Thompson Siegel & Walmsley LLC acquired a new stake in PetMed Express in the third quarter valued at approximately $149,000. Finally, Fred Alger Management Inc. acquired a new stake in PetMed Express in the second quarter valued at approximately $162,000. Institutional investors own 81.30% of the company’s stock.
PetMed Express Company Profile
PetMed Express, Inc (PetMed Express), doing business as 1800PetMeds, is a pet pharmacy. The Company markets prescription and non-prescription pet medications, and other health products for dogs and cats, direct to the consumer. It offers a selection of products for dogs and cats. Its product line contains approximately 3,000 stock keeping units (SKUS) of pet medications, health products and supplies.
Get a free copy of the Zacks research report on PetMed Express (PETS)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for PetMed Express Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PetMed Express Inc. and related companies with MarketBeat.com's FREE daily email newsletter.